KD3010

KD3010 is a potent, orally administered small molecule agonist of peroxisome proliferator-activated receptor delta (PPARδ). It exhibits approximately 1000-fold selectivity for PPARδ over PPARγ and PPARα. By activating PPARδ, which regulates lipid catabolism and energy utilization in peripheral tissues, KD3010 aims to address metabolic disorders such as obesity and diabetes. Preclinical studies have shown that it reduces central adiposity, improves atherogenic lipid profiles, increases glucose utilization/insulin sensitivity, and has hepatoprotective as well as antifibrotic effects in models of liver fibrosis. Additionally, activation of PPARδ by KD3010 has demonstrated benefits in neurodegenerative disease models such as Huntington's disease by improving motor function and reducing neurodegeneration[2][3][4][5][6][7][8]. KD3010 is an investigational drug not approved for human or veterinary use; it remains at the preclinical or early clinical development stage with no known commercial developer or manufacturer identified from available sources.